ArticleFrontiers in bioengineering and biotechnology2024
Development and characterization of a novel injectable thyroid extracellular matrix hydrogel for enhanced thyroid tissue engineering applications.
Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immune Roles of Canonically Non-Immune Cells in Biomaterials Response.Cell biomaterials · 2026Article
- Emerging Roles, Mechanisms, and Therapeutic Potential of Thyroid Hormones in Neurodegenerative Diseases: A Review.Brain sciences · 2026Review
- Research advances in hydrogel-based strategies for thyroid disease management: from diagnosis to therapeutic applications.Frontiers in bioengineering and biotechnology · 2026Review
- Gel Delivery Systems in Dental Medicine: From Controlled Release to Regenerative Applications.Gels (Basel, Switzerland) · 2025Review
- Hydrogel-driven innovations for targeted delivery, immune modulation, and tissue repair in thyroid cancer therapy.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypothyroidism, a condition characterized by decreased synthesis and secretion of thyroid hormones, significantly impacts intellectual development and physical growth. Current treatments, including hormone replacement therapy and thyroid transplantation, have limitations due to issues like hormone dosage control and immune rejection. Tissue engineering presents a potential solution by combining cells and biomaterials to construct engineered thyroid tissue. This study focuses on the development and characterization of a novel 3D injectable hydrogel derived from thyroid extracellular matrix (TEM) for thyroid tissue engineering. TEM hydrogels were prepared through decellularization of rat thyroid tissue, followed by extensive physicochemical and mechanical property evaluations. The TEM hydrogels exhibited properties similar to natural thyroid tissue, including high biocompatibility and a complex 3D ultrastructure. Thyroid hormone-secreting cells cultured in TEM hydrogels demonstrated superior viability, hormone secretion, and thyroid-related gene expression compared to those in traditional type I collagen hydrogels. The study also confirmed the significant retention of key growth factors and ECM proteins within the TEM hydrogels. The results indicate that TEM hydrogels can provide a biomimetic microenvironment, promoting the long-term survival and function of thyroid cells, thus holding great promise for the treatment of hypothyroidism. This research contributes a potential new avenue for thyroid tissue engineering, offering a promising alternative for hypothyroidism treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.